GSK932121
GSK932121 is an antimalarial drug with activity that inhibits the electron transport chain of P. falciparum. GSK932121 acts selectively on this pathogen at the level of cytochrome bc1 (complex III). The synthesis method of GSK932121 is highly efficient, and the final structure can be obtained in only 5 steps. The synthesis of GSK932121 can be prepared atKilog scale to support clinical studies.
For research use only. We do not sell to patients.
- CAS No.: 958457-44-8
- Formula: C20H15ClF3NO4
- Molecular Weight:425.79
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Parasite Isoforms
More
Biological Activity
Description
Chemical Information
-
CAS No. 958457-44-8
-
Molecular Weight 425.79
-
Formula C20H15ClF3NO4
-
SMILES
O=C1C(Cl)=C(C)NC(CO)=C1C2=CC=C(OC3=CC=C(OC(F)(F)F)C=C3)C=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)